OncoMatch/Clinical Trials/NCT05692024
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Is NCT05692024 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule. for colorectal cancer.
Treatment: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule. — This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage I, II, III
Prior therapy
Must have received: surgery — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Must have received: chemotherapy — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Must have received: radiation therapy — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify